Timur Dogan
Directeur Technique/Scientifique/R&D chez CARDIO DIAGNOSTICS HOLDINGS, INC.
Fortune : 92 665 $ au 30/04/2024
Postes actifs de Timur Dogan
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARDIO DIAGNOSTICS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | 25/10/2022 | - |
Historique de carrière de Timur Dogan
Anciens postes connus de Timur Dogan
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Directeur Technique/Scientifique/R&D | 01/05/2022 | - |
Formation de Timur Dogan
University of Iowa | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectorielle
Consumer Services | 2 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
Cardio Diagnostics Holdings, Inc. |
- Bourse
- Insiders
- Timur Dogan
- Expérience